UARK 98-036, a phase II trial of combination bisphosphonate and anti-angiogenesis therapy with pamidronate and thalidomide in patients with smoldering/indolent myeloma

Trial Profile

UARK 98-036, a phase II trial of combination bisphosphonate and anti-angiogenesis therapy with pamidronate and thalidomide in patients with smoldering/indolent myeloma

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2015

At a glance

  • Drugs Pamidronic acid (Primary) ; Thalidomide (Primary) ; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Sep 2013 Planned end date changed from 1 Jul 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 04 Sep 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top